Drugs / IndoVac
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 22 trials | ||||||
| Phase 2 | NCT05933278 | Jul 2023 → Aug 2024 | COVID-19 | PT Bio Farma | Completed | No outcome recorded |
| Phase 2 | NCT05727215 | Feb 2023 → Feb 2024 | COVID-19 | PT Bio Farma | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT05433285 | Jun → Aug 2022 | COVID-19 | PT Bio Farma | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IndoVac | “Bio Farma has developed a recombinant protein subunit vaccine (IndoVac) that is indicated for active immunization in population of all ages.” PMID 38575433 ↗ Apr 20242“Immunogenicity & Safety of IndoVac® as a Homologous Booster Dose Against COVID-19 in Adults Aged 18 Years and Above in Indonesia” NCT05933278 ↗ “Immunogenicity and Safety of IndoVac® as a Heterologous Booster Dose Against COVID-19 in Children 12-17 Years of Age” NCT05727215 ↗ |
| Modality | Vaccine | “recombinant protein subunit vaccine (IndoVac)” PMID 38575433 ↗ Apr 2024 |